Squarepoint Ops LLC lessened its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 46.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,782 shares of the company's stock after selling 6,876 shares during the quarter. Squarepoint Ops LLC's holdings in Praxis Precision Medicines were worth $599,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of PRAX. Janus Henderson Group PLC increased its position in Praxis Precision Medicines by 77.5% during the fourth quarter. Janus Henderson Group PLC now owns 929,523 shares of the company's stock worth $71,621,000 after buying an additional 405,957 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Praxis Precision Medicines during the fourth quarter worth approximately $17,454,000. Millennium Management LLC increased its position in Praxis Precision Medicines by 3,519.4% during the fourth quarter. Millennium Management LLC now owns 150,892 shares of the company's stock worth $11,613,000 after buying an additional 146,723 shares during the last quarter. Norges Bank acquired a new position in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $9,151,000. Finally, CIBC Asset Management Inc grew its position in shares of Praxis Precision Medicines by 47.3% in the fourth quarter. CIBC Asset Management Inc now owns 366,756 shares of the company's stock valued at $28,226,000 after purchasing an additional 117,817 shares during the last quarter. Institutional investors and hedge funds own 67.84% of the company's stock.
Praxis Precision Medicines Stock Performance
Shares of Praxis Precision Medicines stock traded up $0.89 on Thursday, reaching $42.26. 895,672 shares of the stock were exchanged, compared to its average volume of 388,554. The firm's 50 day moving average is $35.76 and its 200-day moving average is $56.47. Praxis Precision Medicines, Inc. has a one year low of $26.70 and a one year high of $91.83. The firm has a market cap of $860.79 million, a PE ratio of -4.10 and a beta of 2.60.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. On average, equities research analysts expect that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year.
Analyst Ratings Changes
PRAX has been the topic of several research reports. Robert W. Baird decreased their target price on Praxis Precision Medicines from $117.00 to $73.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Oppenheimer initiated coverage on Praxis Precision Medicines in a research report on Monday. They issued an "outperform" rating and a $97.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Praxis Precision Medicines in a research report on Tuesday, February 11th. They issued a "buy" rating and a $111.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a research report on Monday, May 5th. Finally, Chardan Capital initiated coverage on Praxis Precision Medicines in a research report on Wednesday, May 7th. They issued a "buy" rating and a $80.00 target price on the stock. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $109.90.
Read Our Latest Report on PRAX
Praxis Precision Medicines Profile
(
Free Report)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Read More

Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.